Chemours Is Maintained at Equal-Weight by Barclays
Chemours Analyst Ratings
Take Care Before Diving Into The Deep End On The Chemours Company (NYSE:CC)
Chemours (NYSE:CC) Investors Are up 5.8% in the Past Week, but Earnings Have Declined Over the Last Five Years
巴克莱银行维持The Chemours(CC.US)持有评级，下调目标价至21美元
Barclays analyst Michael Leithead maintains $The Chemours(CC.US)$ with a hold rating, and adjusts the target price from $22 to $21.According to TipRanks data, the analyst has a success rate of 57.4%
Express News | Chemours : Barclays Cuts Target Price to $21 From $22